Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2015 | 12-2006 | |
| Cash Flows From Operating Activities | ||
| Net Income | -13,153 | N/A |
| Depreciation Amortization | 11 | N/A |
| Accounts payable and accrued liabilities | 671 | N/A |
| Other Working Capital | 170 | N/A |
| Other Operating Activity | 2,693 | 0 |
| Operating Cash Flow | $-9,608 | $N/A |
| Cash Flows From Investing Activities | ||
| PPE Investments | -232 | N/A |
| Investing Cash Flow | $-232 | $N/A |
| Cash Flows From Financing Activities | ||
| Common Stock Issued | 8,000 | N/A |
| Other Financing Activity | 7,275 | 0 |
| Financing Cash Flow | $15,275 | $N/A |
| Beginning Cash Position | 256 | N/A |
| End Cash Position | 5,691 | N/A |
| Net Cash Flow | $5,435 | $N/A |
| Free Cash Flow | ||
| Operating Cash Flow | -9,608 | N/A |
| Capital Expenditure | -232 | N/A |
| Free Cash Flow | -9,840 | 0 |